Pharmacogenetic considerations for late life depression therapy

Pothitos M. Pitychoutis, Nikolaos Kokras, Despina Sanoudou, Christina Dalla, Zeta Papadopoulou-Daifoti

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction: Geriatric depression is a heterogeneous disorder with a complex genetic background. Current first-line treatment of depression is associated with a lower therapeutic outcome in aged depressed patients, when compared to younger subjects. Research which has explored this inadequate response has highlighted several factors which have come into play with the pharmacogenetics of antidepressants in the elderly being a particular area of interest. Areas covered: The authors perform a critical review of the English language articles from PubMed using search terms such as late-life/geriatric depression, antidepressants, pharmacogenetics, pharmacogenomics, pharmacokinetic, genetic, genotype, remission, therapy, treatment and polymorphism. Expert opinion: The emerging clinical and pharmacogenetic data are slowly unveiling the importance of the genome-age interaction in antidepressant response. This data introduces a critical new parameter in personalized medicine. A profound analysis of the age factor in the pharmacogenetics of antidepressant response is imperative, in order to elucidate the clinical significance of these findings and thereby improve patient treatment in the elderly.

Original languageEnglish
Pages (from-to)989-999
Number of pages11
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume9
Issue number8
DOIs
Publication statusPublished - 1 Aug 2013
Externally publishedYes

Fingerprint

Pharmacogenetics
Antidepressive Agents
Depression
Geriatrics
Patient treatment
Therapeutics
Precision Medicine
Pharmacokinetics
Age Factors
Expert Testimony
Polymorphism
PubMed
Medicine
Language
Genes
Genotype
Genome
Research

Keywords

  • 5-HTT gene-linked polymorphic region
  • Antidepressant drug
  • Brain-derived neurotrophic factor
  • Citalopram
  • Cytochrome P450
  • Dopamine transporter 1
  • Elderly
  • Geriatric depression
  • Remission
  • Serotonin transporter
  • Stressful life episodes
  • Treatment

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Pitychoutis, P. M., Kokras, N., Sanoudou, D., Dalla, C., & Papadopoulou-Daifoti, Z. (2013). Pharmacogenetic considerations for late life depression therapy. Expert Opinion on Drug Metabolism and Toxicology, 9(8), 989-999. https://doi.org/10.1517/17425255.2013.794786

Pharmacogenetic considerations for late life depression therapy. / Pitychoutis, Pothitos M.; Kokras, Nikolaos; Sanoudou, Despina; Dalla, Christina; Papadopoulou-Daifoti, Zeta.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, No. 8, 01.08.2013, p. 989-999.

Research output: Contribution to journalArticle

Pitychoutis, PM, Kokras, N, Sanoudou, D, Dalla, C & Papadopoulou-Daifoti, Z 2013, 'Pharmacogenetic considerations for late life depression therapy', Expert Opinion on Drug Metabolism and Toxicology, vol. 9, no. 8, pp. 989-999. https://doi.org/10.1517/17425255.2013.794786
Pitychoutis, Pothitos M. ; Kokras, Nikolaos ; Sanoudou, Despina ; Dalla, Christina ; Papadopoulou-Daifoti, Zeta. / Pharmacogenetic considerations for late life depression therapy. In: Expert Opinion on Drug Metabolism and Toxicology. 2013 ; Vol. 9, No. 8. pp. 989-999.
@article{20837763f74a4158b32fcc47a97201ea,
title = "Pharmacogenetic considerations for late life depression therapy",
abstract = "Introduction: Geriatric depression is a heterogeneous disorder with a complex genetic background. Current first-line treatment of depression is associated with a lower therapeutic outcome in aged depressed patients, when compared to younger subjects. Research which has explored this inadequate response has highlighted several factors which have come into play with the pharmacogenetics of antidepressants in the elderly being a particular area of interest. Areas covered: The authors perform a critical review of the English language articles from PubMed using search terms such as late-life/geriatric depression, antidepressants, pharmacogenetics, pharmacogenomics, pharmacokinetic, genetic, genotype, remission, therapy, treatment and polymorphism. Expert opinion: The emerging clinical and pharmacogenetic data are slowly unveiling the importance of the genome-age interaction in antidepressant response. This data introduces a critical new parameter in personalized medicine. A profound analysis of the age factor in the pharmacogenetics of antidepressant response is imperative, in order to elucidate the clinical significance of these findings and thereby improve patient treatment in the elderly.",
keywords = "5-HTT gene-linked polymorphic region, Antidepressant drug, Brain-derived neurotrophic factor, Citalopram, Cytochrome P450, Dopamine transporter 1, Elderly, Geriatric depression, Remission, Serotonin transporter, Stressful life episodes, Treatment",
author = "Pitychoutis, {Pothitos M.} and Nikolaos Kokras and Despina Sanoudou and Christina Dalla and Zeta Papadopoulou-Daifoti",
year = "2013",
month = "8",
day = "1",
doi = "10.1517/17425255.2013.794786",
language = "English",
volume = "9",
pages = "989--999",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Pharmacogenetic considerations for late life depression therapy

AU - Pitychoutis, Pothitos M.

AU - Kokras, Nikolaos

AU - Sanoudou, Despina

AU - Dalla, Christina

AU - Papadopoulou-Daifoti, Zeta

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Introduction: Geriatric depression is a heterogeneous disorder with a complex genetic background. Current first-line treatment of depression is associated with a lower therapeutic outcome in aged depressed patients, when compared to younger subjects. Research which has explored this inadequate response has highlighted several factors which have come into play with the pharmacogenetics of antidepressants in the elderly being a particular area of interest. Areas covered: The authors perform a critical review of the English language articles from PubMed using search terms such as late-life/geriatric depression, antidepressants, pharmacogenetics, pharmacogenomics, pharmacokinetic, genetic, genotype, remission, therapy, treatment and polymorphism. Expert opinion: The emerging clinical and pharmacogenetic data are slowly unveiling the importance of the genome-age interaction in antidepressant response. This data introduces a critical new parameter in personalized medicine. A profound analysis of the age factor in the pharmacogenetics of antidepressant response is imperative, in order to elucidate the clinical significance of these findings and thereby improve patient treatment in the elderly.

AB - Introduction: Geriatric depression is a heterogeneous disorder with a complex genetic background. Current first-line treatment of depression is associated with a lower therapeutic outcome in aged depressed patients, when compared to younger subjects. Research which has explored this inadequate response has highlighted several factors which have come into play with the pharmacogenetics of antidepressants in the elderly being a particular area of interest. Areas covered: The authors perform a critical review of the English language articles from PubMed using search terms such as late-life/geriatric depression, antidepressants, pharmacogenetics, pharmacogenomics, pharmacokinetic, genetic, genotype, remission, therapy, treatment and polymorphism. Expert opinion: The emerging clinical and pharmacogenetic data are slowly unveiling the importance of the genome-age interaction in antidepressant response. This data introduces a critical new parameter in personalized medicine. A profound analysis of the age factor in the pharmacogenetics of antidepressant response is imperative, in order to elucidate the clinical significance of these findings and thereby improve patient treatment in the elderly.

KW - 5-HTT gene-linked polymorphic region

KW - Antidepressant drug

KW - Brain-derived neurotrophic factor

KW - Citalopram

KW - Cytochrome P450

KW - Dopamine transporter 1

KW - Elderly

KW - Geriatric depression

KW - Remission

KW - Serotonin transporter

KW - Stressful life episodes

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84880344147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880344147&partnerID=8YFLogxK

U2 - 10.1517/17425255.2013.794786

DO - 10.1517/17425255.2013.794786

M3 - Article

VL - 9

SP - 989

EP - 999

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 8

ER -